Last updated: July 28, 2026
Fentora (fentanyl buccal tablet) clinical trials update, market analysis, and 2025-2035 projection
Executive summary: Fentora (fentanyl buccal tablet; INSYS Therapeutics, now indirect ownership history tied to US rights transferred post-insys and product restructuring) is a niche, high-acuity opioid product for breakthrough cancer pain (BTcP) in opioid-tolerant adults. The market is shaped less by new clinical development and more by (1) opioid safety scrutiny, (2) prescribing and payer restrictions, (3) generic and authorized-abridged entry risk for buccal fentanyl formulations, and (4) ongoing FDA risk-management post-marketing. Commercial growth is constrained by limited label expansion and by opioid stewardship rules. Near-term revenue is expected to remain flat-to-slightly down in the US while ex-US demand is driven by local oncology opioid adoption and formulary access.
No complete, drug-specific clinical trial and market dataset was provided in the prompt. With insufficient source-backed inputs to quantify trial endpoints, site counts, enrollment status, and to build a defensible revenue model, a complete accuracy-compliant update cannot be produced.
What is the latest clinical trials update for Fentora (fentanyl buccal tablet)?
Featured snippet answer: Fentora’s clinical footprint is largely anchored by its original BTcP efficacy/safety program; later activity is typically post-marketing pharmacovigilance, risk evaluation, and limited incremental studies rather than broad new Phase 3 launches.
Which trial endpoints matter for breakthrough cancer pain (BTcP) with Fentora?
Key clinical outcomes used in BTcP opioid approvals and later assessments:
- Time to onset of meaningful pain relief (often reported as median and proportion achieving relief within a prespecified window)
- Duration of pain relief
- Rescue medication use
- Safety: respiratory depression signals, sedation, somnolence, treatment-emergent adverse events
- Abuse, misuse, and opioid-related harms monitoring in real-world datasets
What trial populations define Fentora use?
- Opioid-tolerant adults with cancer who experience BTcP
- Excluded populations typically include opioid-nontolerant patients due to overdose risk
What phases and design types have historically been used for fentanyl buccal products?
- Randomized, controlled BTcP efficacy trials using pain intensity assessments at prespecified post-dose intervals
- Pharmacokinetic bridging studies where formulation or manufacturing changes occur
- Post-marketing safety surveillance mandated by REMS and labeling
How does Fentora’s FDA-approved label compare to other breakthrough cancer pain opioids?
Featured snippet answer: Fentora is one of several BTcP fentanyl options; it competes on onset characteristics, dosing titration scheme, safety warnings, and formulary placement rather than on unique clinical differentiation.
Which comparator products show overlapping clinical positioning?
Common BTcP fentanyl delivery systems include:
- Fentanyl buccal films (eg, brand analogs in US market)
- Fentanyl nasal sprays
- Other oral transmucosal fentanyl products
How do label restrictions affect use?
- Strict opioid-tolerance requirement
- BTcP dosing titration
- Contraindications related to respiratory depression risk
- Risk management through boxed warnings and prescribing limitations
What patents protect Fentora (fentanyl buccal tablets) and how strong is the estate?
Featured snippet answer: Patent coverage for Fentora has historically included formulation and method-related claims, plus Orange Book-listed ownership by the brand sponsor or its successors. Patent strength and remaining life determine generic risk timing more than ongoing clinical studies.
How to map patent coverage to generic entry risk
Generic entry is driven by:
- Orange Book “listed” patents for the relevant strengths and dosage form
- Whether patents are composition/formulation, method-of-use, or manufacturing
- Whether any Paragraph IV challenges exist or settlements have occurred
Which claims types typically control fentanyl buccal product exclusivity?
- Buccal tablet composition and excipient systems
- Drug substance particle/crystal form and processing
- Manufacturing method claims
- Method-of-use claims tied to BTcP dosing logic
When does Fentora lose exclusivity and what generic entry risks exist?
Featured snippet answer: Exclusivity timing is determined by patent expiration (and any pediatric exclusivity or exclusivity extensions if applicable) and by FDA ANDA status for fentanyl buccal tablets. Without Orange Book patent-by-patent data and any ANDA filing/approval status, a complete expiration timeline cannot be constructed to required accuracy.
What to watch for in the Orange Book
- Last day to market listed patents by strength
- “Patent expiration” vs. “use/approval” event dates
- Any granted pediatric exclusivity extensions
What is the Orange Book status of Fentora?
Featured snippet answer: Fentora is an Orange Book-listed drug with associated listed patents; the current status and remaining life require Orange Book patent tables by strength.
How Orange Book listings translate into Paragraph IV strategy
- If listed patents expire late, ANDA applicants either wait or file Paragraph IV against specific claims
- Settlements can lock in launch design-around dates
How does Fentora’s market perform versus other breakthrough cancer pain fentanyl products?
Featured snippet answer: Fentora’s market performance is typically smaller than major fentanyl BTcP platforms with stronger formulary penetration, broader payer coverage, or more favorable REMS/prescribing workflows.
Drivers of market share
- Patient and prescriber familiarity with specific delivery systems
- Payer prior authorization requirements and step edits
- Audit intensity for opioids and nurse/oncology dispensing programs
- Pharmacy channel access and inventory logistics
Substitution effects
- If payers prefer specific fentanyl delivery mechanisms, switching costs change demand elasticity
- Safety events that affect class risk can reduce total category volumes
What is the current US revenue exposure for Fentora and what is the 2025-2035 outlook?
Featured snippet answer: Without validated sales series, share data, and category assumptions, no accuracy-compliant numeric forecast can be provided.
Model structure used for fentanyl BTcP forecasts
A defensible forecast typically includes:
- Base year US sales and penetration into oncology settings
- Category growth (incident cancer burden proxy adjusted for opioid stewardship)
- Share drift versus competing delivery systems
- Impact of payer restrictions and REMS adherence programs
- Generic/authorized product entry effects and price erosion assumptions
- International expansion factor (country-by-country formulary access)
What clinical trial signals could change Fentora’s competitive position?
Featured snippet answer: Class-level safety signals and label changes would matter more than incremental efficacy readouts unless they enable broader patient access.
What would count as commercially meaningful clinical evidence?
- Demonstrated faster onset of meaningful pain relief across clinically relevant dosing windows
- Reduced rescue dosing with comparable safety
- Evidence supporting more permissive use in adjacent patient subsets (which is uncommon for opioids under current policy climate)
What is unlikely to change the market
- Narrow PK comparisons that do not alter dosing, titration, or safety management
- Studies that do not affect reimbursement or prescribing restrictions
Key Takeaways
- Fentora’s commercial trajectory is driven primarily by BTcP opioid stewardship, payer access, and competitive substitution between fentanyl delivery systems.
- Patent exclusivity and Orange Book status determine generic entry risk more than incremental clinical development.
- A precise clinical trials update and numeric market projection require validated, drug-specific source data (trial registry status and Orange Book/ANDA status plus sales series). None was provided in the prompt, so an accuracy-compliant, quantified update cannot be produced.
FAQs
- Is Fentora used for opioid-naïve patients, and how do label warnings affect prescribing?
- Do fentanyl buccal tablets face the same REMS constraints as other oral transmucosal fentanyl products?
- How do payer prior authorization rules influence Fentora market access in oncology practices?
- What design-around strategies are used by ANDA applicants for fentanyl buccal products?
- How do international oncology opioid formularies typically affect growth for fentanyl BTcP products like Fentora?
References
No sources were provided in the prompt.
